Trade Protara Therapeutics, Inc. - TARA CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.07 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 2.94 |
| Open | 3.14 |
| 1-Year Change | 2.95% |
| Day's Range | 2.82 - 3.14 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| May 10, 2024 | 2.96 | -0.12 | -3.90% | 3.08 | 3.24 | 2.81 |
| May 9, 2024 | 2.94 | 0.16 | 5.76% | 2.78 | 3.20 | 2.78 |
| May 8, 2024 | 2.81 | -0.02 | -0.71% | 2.83 | 2.90 | 2.78 |
| May 7, 2024 | 2.85 | -0.03 | -1.04% | 2.88 | 2.93 | 2.85 |
| May 6, 2024 | 2.87 | 0.02 | 0.70% | 2.85 | 2.99 | 2.84 |
| May 3, 2024 | 2.86 | -0.01 | -0.35% | 2.87 | 2.96 | 2.79 |
| May 2, 2024 | 2.85 | -0.04 | -1.38% | 2.89 | 2.94 | 2.82 |
| May 1, 2024 | 2.88 | -0.03 | -1.03% | 2.91 | 3.09 | 2.83 |
| Apr 30, 2024 | 2.94 | -0.09 | -2.97% | 3.03 | 3.03 | 2.81 |
| Apr 29, 2024 | 3.03 | 0.22 | 7.83% | 2.81 | 3.13 | 2.81 |
| Apr 26, 2024 | 2.89 | -0.24 | -7.67% | 3.13 | 3.14 | 2.78 |
| Apr 25, 2024 | 3.00 | 0.21 | 7.53% | 2.79 | 3.01 | 2.73 |
| Apr 24, 2024 | 2.78 | -0.20 | -6.71% | 2.98 | 3.04 | 2.78 |
| Apr 23, 2024 | 2.98 | -0.02 | -0.67% | 3.00 | 3.11 | 2.79 |
| Apr 22, 2024 | 3.03 | -0.02 | -0.66% | 3.05 | 3.23 | 2.85 |
| Apr 19, 2024 | 2.59 | -0.06 | -2.26% | 2.65 | 2.74 | 2.59 |
| Apr 18, 2024 | 2.70 | -0.07 | -2.53% | 2.77 | 2.83 | 2.63 |
| Apr 17, 2024 | 2.71 | -0.01 | -0.37% | 2.72 | 2.78 | 2.63 |
| Apr 16, 2024 | 2.83 | 0.09 | 3.28% | 2.74 | 2.87 | 2.68 |
| Apr 15, 2024 | 2.81 | -0.17 | -5.70% | 2.98 | 2.98 | 2.77 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Protara Therapeutics, Inc. Company profile
About Protara Therapeutics Inc
Protara Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying therapies for the treatment of cancer and rare diseases. The Company's pipeline includes TARA-002, IV Choline Chloride and Vonapanitase. The Company's lead product pipeline is TARA 002 for the treatment of non-muscle invasive bladder cancer (NMIBC) and Lymphatic Malformations (LMs). TARA 002 is a cellular therapy based on OK-432, also known as Picibanil, which is derived from a genetically distinct strain of Streptococcus Pyogenes. IV choline chloride is intravenous (IV) substrate replacement therapy for patients with choline deficiency who exhibit symptoms of liver impairment. IV Choline Chloride is being developed for the treatment of Intestinal Failure Associated Liver Disease (IFALD). Vonapanitase is a recombinant human elastase that are developing for the improvement of vascular access outcomes in patients with chronic kidney disease.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Protara Therapeutics Inc revenues was not reported. Net loss increased 39% to $47.3M. Higher net loss reflects Research and development - other increase of 75% to $19.7M (expense), General and administrative - other increase of 30% to $17.4M (expense), Stock-based Compensation in Research and increase of 90% to $1.4M (expense).
| Industry: | Bio Therapeutic Drugs |
345 Park Avenue South
3rd Floor
NEW YORK
NEW YORK 10010
US
News
Stock market crash: how far can the S&P 500 go?
After a remarkably strong first quarter, the US stock market pulled back in April for the first time since October last year.
11:46, 10 May 2024
Bank of England preview: possible rate cut in summer?
The Bank of England (BoE) is widely expected to keep interest rates unchanged when it meets later this week. Data from Reuters shows a 90% chance of no change to the current rate of 5.25%, but the central bank will need to decide whether to change the messaging about rate cuts this year as traders will be paying close attention to any rate-cut clues.
12:39, 8 May 2024
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024
US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com